Q1 2014 13F Holders as of 31 Mar 2014
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
11,038,114
-
Share change
-
+11,038,114
-
Total reported value
-
$200,671,000
-
Price per share
-
$18.18
-
Number of holders
-
35
-
Value change
-
+$200,671,000
-
Number of buys
-
35
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2014
As of 31 Mar 2014,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,038,114 shares.
The largest 10 holders included
FMR LLC, BlackRock Advisors LLC, Redmile Group, LLC, FRANKLIN RESOURCES INC, Visium Asset Management, LP, ADAGE CAPITAL PARTNERS GP LLC, WALL STREET ASSOCIATES, BlackRock Group LTD, VANGUARD GROUP INC, and Broadfin Capital, LLC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q1 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.